A study has found a new biomarker of schizophrenia that can serve as a target for drugs treating cognitive decline. The study conducted by US' Northwestern University found a brain and spinal protein lacking among schizophrenia patients. Researchers added that they created a synthetic version of the protein and found that it can correct abnormal brain activity and behavioural problems.